ARTICLE | Clinical News
Brincidofovir: Phase III started
November 2, 2015 8:00 AM UTC
Chimerix began the double-blind, active-controlled, Phase III SURPASS trial to compare twice-weekly 100 mg brincidofovir vs. valganciclovir for up to 14 weeks post-transplant in about 520 kidney trans...